CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 183 enrolled
Drug / intervention
amlodipine 5/10 mg per day plus valsartan 160 mg/day +1 moredrug
Likely dose
amlodipine 5/10 mg per day plus valsartan 160 mg/dayfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01030458
NCT01030458Phase 4Completed

Newer vs Older Antihypertensive Agents in African Hypertensive Patients Trial

KU Leuven·interventional·Posted Dec 11, 2009·Updated Dec 9, 2013

In Brief

A Phase 4 clinical trial evaluating amlodipine 5/10 mg per day plus valsartan 160 mg/day and hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day for Blood Pressure. Completed, enrolled 183 participants across 7 sites in 5 countries.

Detailed Summary

The purpose of this study is to compare the blood pressure lowering efficacy of a treatment regimen based on a dihydropyridine calcium-channel blocker combined with an angiotensin II type-1 receptor blocker with the recommended treatment regimen based on a low-dose thiazide diuretic combined with a beta-blocker.

Study Details

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 11, 2009
Enrollment StartSep 1, 2010
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 16.6 years ago

Interventions

amlodipine 5/10 mg per day plus valsartan 160 mg/daydrug

Amlodipine 5/10 mg/day plus valsartan 160 mg/day, once daily, in the morning

hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/daydrug

hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning